Systems biology describes a holistic and integrative approach to understand physiology and pathology. The “omic” disciplines include genomics, transcriptomics, proteomics, and metabolic profiling (metabonomics and metabolomics). By adopting a stance, which is opposing (yet complimentary) to conventional research techniques, systems biology offers an overview by assessing the “net” biological effect imposed by a disease or nondisease state. There are a number of different organizational levels to be understood, from DNA to protein, metabolites, cells, organs and organisms, even beyond this to an organism’s context. Systems biology relies on the existence of “nodes” and “edges.” Nodes are the constituent part of the system being studied (eg, proteins in the proteome), while the edges are the way these constituents interact. In future, it will be increasingly important to collaborate, collating data from multiple studies to improve data sets, making them freely available and undertaking integrative analyses.
NarulaJStraussHW. The popcorn plaques. Nat Med. 2007;13(5):532–534.
2.
ShalhoubJDaviesKJHasanNThaparASharmaPDaviesAH. The utility of collaborative biobanks for cardiovascular research. Angiology. 2012;63(5):367–377.
3.
RossR. Atherosclerosis--an inflammatory disease. N Engl J Med. 1999;340(2):115–126.
4.
AndersonPW. More is different. Science. 1972;177(4047):393–396.
5.
PrigogineIStengersI. La nouvelle alliance. Paris: Editions Gallimard; 1979.
6.
FerrellJEJrQ&A: Systems biology. J Biol. 2009;8(1):2.
7.
KirschnerMW. The meaning of systems biology. Cell. 2005;121(4):503–504.
8.
VarkiAAltheideTK. Comparing the human and chimpanzee genomes: Searching for needles in a haystack. Genome Res. 2005;15(12):1746–1758.
9.
LanderAD. The edges of understanding. BMC Biol. 2010;8:40.
10.
HartwellLHHopfieldJJLeiblerSMurrayAW. From molecular to modular cell biology. Nature. 1999;402(6761 suppl):C47–C52.
11.
SoutarAKNaoumovaRP. Mechanisms of disease: Genetic causes of familial hypercholesterolemia. Nat Clin Pract Cardiovasc Med. 2007;4(4):214–225.
12.
De KeulenaerGWBrutsaertDL. Systolic and diastolic heart failure are overlapping phenotypes within the heart failure spectrum. Circulation. 2011;123(18):1996–2004.
13.
FraylingTMTimpsonNJWeedonMN. A common variant in the fto gene is associated with body mass index and predisposes to childhood and adult obesity. Science. 2007;316(5826):889–894.
14.
BarabasiAL. Network medicine--from obesity to the “diseasome”. N Engl J Med. 2007;357(4):404–407.
15.
ChristakisNAFowlerJH. The spread of obesity in a large social network over 32 years. N Engl J Med. 2007;357(4):370–379.
16.
LusisAJWeissJN. Cardiovascular networks: Systems-based approaches to cardiovascular disease. Circulation. 2010;121(1):157–170.
RamseySAKlemmSLZakDE. Uncovering a macrophage transcriptional program by integrating evidence from motif scanning and expression dynamics. PLoS Comput Biol. 2008;4(3):e1000021.
19.
WareJH. The limitations of risk factors as prognostic tools. N Engl J Med. 2006;355(25):2615–2617.
20.
GersztenREWangTJ. The search for new cardiovascular biomarkers. Nature. 2008;451(7181):949–952.
21.
PepeMSThompsonML. Combining diagnostic test results to increase accuracy. Biostatistics. 2000;1(2):123–140.
22.
HumphriesSEMorganL. Genetic risk factors for stroke and carotid atherosclerosis: insights into pathophysiology from candidate gene approaches. Lancet Neurol. 2004;3(4):227–235.
23.
KostulasKBrophyVHMoraitisK. Genetic profile of ischemic cerebrovascular disease and carotid stenosis. Acta Neurol Scand. 2008;118(3):146–152.
24.
LanktreeMBHegeleRAYusufSAnandSS. Multi-ethnic genetic association study of carotid intima-media thickness using a targeted cardiovascular snp microarray. Stroke. 2009;40(10):3173–3179.
25.
Newton-ChehCJohnsonTGatevaV. Genome-wide association study identifies eight loci associated with blood pressure. Nat Genet. 2009;41(6):666–676.
26.
ArchackiSRWangQK. Microarray analysis of cardiovascular diseases. Methods Mol Med. 2006;129:1–13.
27.
ArchackiSRAngheloiuGTianXL. Identification of new genes differentially expressed in coronary artery disease by expression profiling. Physiol Genomics. 2003;15(1):65–74.
28.
RandiAMBiguzziEFalcianiF. Identification of differentially expressed genes in coronary atherosclerotic plaques from patients with stable or unstable angina by cdna array analysis. J Thromb Haemost. 2003;1(4):829–835.
29.
ArchackiSWangQ. Expression profiling of cardiovascular disease. Hum Genomics. 2004;1(5):355–370.
30.
HiltunenMOTuomistoTTNiemiM. Changes in gene expression in atherosclerotic plaques analyzed using DNA array. Atherosclerosis. 2002;165(1):23–32.
31.
FuSZhaoHShiJ. Peripheral arterial occlusive disease: global gene expression analyses suggest a major role for immune and inflammatory responses. BMC Genomics. 2008;9:369.
32.
TabibiazarRWagnerRAAshleyEA. Signature patterns of gene expression in mouse atherosclerosis and their correlation to human coronary disease. Physiol Genomics. 2005;22(2):213–226.
33.
BijnensAPLutgensEAyoubiTKuiperJHorrevoetsAJDaemenMJ. Genome-wide expression studies of atherosclerosis: critical issues in methodology, analysis, interpretation of transcriptomics data. Arterioscler Thromb Vasc Biol. 2006;26(6):1226–1235.
SluimerJCKistersNCleutjensKB. Dead or alive: gene expression profiles of advanced atherosclerotic plaques from autopsy and surgery. Physiol Genomics. 2007;30(3):335–341.
36.
PapaspyridonosMSmithABurnandKG. Novel candidate genes in unstable areas of human atherosclerotic plaques. Arterioscler Thromb Vasc Biol. 2006;26(8):1837–1844.
37.
RossiLLapiniIMagiA. Carotid artery disease: Novel pathophysiological mechanisms identified by gene-expression profiling of peripheral blood. Eur J Vasc Endovasc Surg. 2010;40(5):549–558.
38.
FaberBCCleutjensKBNiessenRL. Identification of genes potentially involved in rupture of human atherosclerotic plaques. Circ Res. 2001;89(6):547–554.
39.
BagnatoCThumarJMayyaV. Proteomics analysis of human coronary atherosclerotic plaque: a feasibility study of direct tissue proteomics by liquid chromatography and tandem mass spectrometry. Mol Cell Proteomics. 2007;6(6):1088–1102.
40.
YouSAArchackiSRAngheloiuG. Proteomic approach to coronary atherosclerosis shows ferritin light chain as a significant marker: evidence consistent with iron hypothesis in atherosclerosis. Physiol Genomics. 2003;13(1):25–30.
41.
Martinez-PinnaRBarbasCBlanco-ColioLM. Proteomic and metabolomic profiles in atherothrombotic vascular disease. Curr Atheroscler Rep. 2010;12(3):202–208.
42.
StegemannCDrozdovIShalhoubJ. Comparative lipidomics profiling of human atherosclerotic plaques. Circ Cardiovasc Genet. 2011;4(3):232–242.
43.
Abdul-SalamVBRamrakhaPKrishnanU. Identification and assessment of plasma lysozyme as a putative biomarker of atherosclerosis. Arterioscler Thromb Vasc Biol. 2010;30(5):1027–1033.
44.
ChenXLiuLPalaciosG. Plasma metabolomics reveals biomarkers of the atherosclerosis. J Sep Sci. 2010;33(17-18):2776–2783.
45.
LepeddaAJCiglianoACherchiGM. A proteomic approach to differentiate histologically classified stable and unstable plaques from human carotid arteries. Atherosclerosis. 2009;203(1):112–118.
46.
MayrMGraingerDMayrU. Proteomics, metabolomics, and immunomics on microparticles derived from human atherosclerotic plaques. Circ Cardiovasc Genet. 2009;2(4):379–388.
47.
BrindleJTAnttiHHolmesE. Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using 1h-nmr-based metabonomics. Nat Med. 2002;8(12):1439–1444.
48.
DidangelosASimperDMonacoCMayrM. Proteomics of acute coronary syndromes. Curr Atheroscler Rep. 2009;11(3):188–195.
49.
DidangelosAStegemannCMayrM. The -omics era: proteomics and lipidomics in vascular research. Atherosclerosis. 2011;221(1):12–17.
50.
Martin-VenturaJLDuranMCBlanco-ColioLM. Identification by a differential proteomic approach of heat shock protein 27 as a potential marker of atherosclerosis. Circulation. 2004;110(15):2216–2219.
51.
DidangelosAYinXMandalKBaumertMJahangiriMMayrM. Proteomics characterization of extracellular space components in the human aorta. Mol Cell Proteomics. 2010;9(9):2048–2062.
52.
NicholsonJKLindonJC. Systems biology: metabonomics. Nature. 2008;455(7216):1054–1056.
53.
NicholsonJKLindonJC, Holmes E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological nmr spectroscopic data. Xenobiotica. 1999;29(11):1181–1189.
54.
ChanECPasikantiKKNicholsonJK. Global urinary metabolic profiling procedures using gas chromatography-mass spectrometry. Nat Protoc. 2011;6(10):1483–1499.
55.
LindonJCHolmesENicholsonJK. Metabonomics techniques and applications to pharmaceutical research & development. Pharm Res. 2006;23(6):1075–1088.
56.
HiraiMYKleinMFujikawaY. Elucidation of gene-to-gene and metabolite-to-gene networks in arabidopsis by integration of metabolomics and transcriptomics. J Biol Chem. 2005;280(27):25590–25595.
57.
BeckonertOKeunHCEbbelsTM. Metabolic profiling, metabolomic and metabonomic procedures for nmr spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc. 2007;2(11):2692–2703.
58.
BeckonertOCoenMKeunHC. High-resolution magic-angle-spinning nmr spectroscopy for metabolic profiling of intact tissues. Nat Protoc. 2010;5(6):1019–1032.
59.
GoonewardenaSNPrevetteLEDesaiAA. Metabolomics and atherosclerosis. Curr Atheroscler Rep. 2010;12(4):267–272.
60.
SchmidtC. Metabolomics takes its place as latest up-and-coming “omic” science. J Natl Cancer Inst. 2004;96(10):732–734.
61.
BunchJClenchMRRichardsDS. Determination of pharmaceutical compounds in skin by imaging matrix-assisted laser desorption/ionisation mass spectrometry. Rapid Commun Mass Spectrom. 2004;18(24):3051–3060.
62.
McDonnellLAHeerenRM. Imaging mass spectrometry. Mass Spectrom Rev. 2007;26(4):606–643.
63.
TrimPJDjidjaMCAtkinsonSJ. Introduction of a 20 khz nd: Yvo4 laser into a hybrid quadrupole time-of-flight mass spectrometer for maldi-ms imaging. Anal Bioanal Chem. 2010;397(8):3409–3419.
64.
TrimPJHensonCMAveryJL. Matrix-assisted laser desorption/ionization-ion mobility separation-mass spectrometry imaging of vinblastine in whole body tissue sections. Anal Chem. 2008;80(22):8628–8634.
65.
SimpsonJCWellenreutherRPoustkaAPepperkokRWiemannS. Systematic subcellular localization of novel proteins identified by large-scale cdna sequencing. EMBO Rep. 2000;1(3):287–292.
66.
KumarAAgarwalSHeymanJA. Subcellular localization of the yeast proteome. Genes Dev. 2002;16(6):707–719.
67.
DjidjaMCClaudeESnelMF. Novel molecular tumour classification using maldi-mass spectrometry imaging of tissue micro-array. Anal Bioanal Chem. 2010;397(2):587–601.
68.
StoeckliMChaurandPHallahanDECaprioliRM. Imaging mass spectrometry: a new technology for the analysis of protein expression in mammalian tissues. Nat Med. 2001;7(4):493–496.
69.
GreyACGelascoAKSectionJMoreno-RodriguezRAKrugELScheyKL. Molecular morphology of the chick heart visualized by maldi imaging mass spectrometry. Anat Rec (Hoboken). 2010;293(5):821–828.
70.
TakatsZWisemanJMGologanBCooksRG. Mass spectrometry sampling under ambient conditions with desorption electrospray ionization. Science. 2004;306(5695):471–473.
71.
ManickeNENefliuMWuC. Imaging of lipids in atheroma by desorption electrospray ionization mass spectrometry. Anal Chem. 2009;81(21):8702–8707.
72.
TryggJHolmesELundstedtT. Chemometrics in metabonomics. J Proteome Res. 2007;6(2):469–479.
73.
van der GreefJSmildeAK. Symbiosis of chemometrics and metabolomics: past, present, and future. J Chemometrics. 2005;19(5-7):376–386.
74.
YeungKYRuzzoWL. Principal component analysis for clustering gene expression data. Bioinformatics. 2001;17(9):763–774.
75.
ScholzMSelbigJ. Visualization and analysis of molecular data. Methods Mol Biol. 2007;358:87–104.
76.
JolliffeIT. Principal component analysis. New York: Springer; 2002.
77.
LutzULutzRWLutzWK. Metabolic profiling of glucuronides in human urine by lc-ms/ms and partial least-squares discriminant analysis for classification and prediction of gender. Anal Chem. 2006;78(13):4564–4571.
78.
BylesjoMRantalainenMCloarecONicholsonJKHolmesETryggJ.Opls discriminant analysis: Combining the strengths of pls-da and simca classification. J Chemometrics. 2006;20(8-10):341–351.
79.
ErikssonL. Cv–anova for significance testing of pls and opls® models. J Chemometrics. 2008;22(11-12):594–600.
80.
BlaiseBJShintuLElenaBndEmsleyLDumasM-EToulhoatP.Statistical recoupling prior to significance testing in nuclear magnetic resonance based metabonomics. Anal Chem. 2009;81(15):6242–6251.
81.
SchadtEELambJYangX. An integrative genomics approach to infer causal associations between gene expression and disease. Nat Genet. 2005;37(7):710–717.
82.
YangXDeignanJLQiH. Validation of candidate causal genes for obesity that affect shared metabolic pathways and networks. Nat Genet. 2009;41(4):415–423.
